彩讯股份 reported revenue of ¥0.70B for the period ended 2026-06-30, -24.3% year on year. Net income was ¥0.07B, a 10.0% net margin on a 38.5% gross margin. The largest revenue line is 智慧渠道产品线 at 50% of the total. Free cash flow for the period was ¥-0.06B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.70B | -24.3% |
| Gross profit | ¥0.27B | — |
| Operating income | ¥0.06B | — |
| Net income | ¥0.07B | -48.5% |
| Gross margin | 38.5% | Net margin 10.0% |
| Revenue Q/Q | +9.8% | — |
| Segment | Revenue | Share |
|---|---|---|
| 智慧渠道产品线 | ¥0.35B | 50.2% |
| 智算服务与数据智能产品线 | ¥0.17B | 23.8% |
| 协同办公产品线 | ¥0.15B | 22.2% |
| 其他(补充) | ¥0.03B | 3.8% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.43B | 61.5% |
| R&D | ¥0.15B | 21.1% |
| SG&A | ¥0.04B | 5.4% |
| Tax & other | ¥-0.01B | -1.8% |
| Item | Amount |
|---|---|
| Total assets | ¥3.80B |
| Total liabilities | ¥0.75B |
| Shareholders' equity | ¥3.05B |
| Equity / assets | 80.2% |
| Operating cash flow | ¥-0.05B |
| Capital expenditure | ¥0.01B |
| Free cash flow | ¥-0.06B |
| Cash conversion (OCF / net income) | -137% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
中达安 ・ 同和药业 ・ 扬帆新材 ・ 广和通 ・ 凯普生物 ・ 德艺文创 ・ 正丹股份 ・ 透景生命 ・ 万通智控 ・ 南京聚隆 ・ 正元智慧 ・ 超频三
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies